CareLit · DOI-Nachweis · Klinische Pädiatrie
Evaluation of clinical responses following long-term infusion of anti-GD2 antibody ch14.18/CHO in high-risk neuroblastoma patients
DOI 10.1055/s-0033-1343657
Bibliografische Angaben
Nachweis in CareLit
Autor:innenI Müller, S Kietz, HN Lode
ZeitschriftKlinische Pädiatrie
Ausgabe05/2013
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Purpose: GD2 is highly expressed in neuroblastoma (NB) and specifically recognized by antibody ch14.18/CHO. Immunotherapy with bolus infusion of ch14.18 in combination with cytokines effectively prolonged survival associated with substancial toxicity. Therefore, we piloted a treatment using continuous infusion of ch14.18 and report first results of clinical responses. Methodes and Marterials: Clinical response was a…
Zitieren
Zitierempfehlung
I Müller, S Kietz, HN Lode (2013) Evaluation of clinical responses following long-term infusion of anti-GD2 antibody ch14.18/CHO in high-risk neuroblastoma patients. Klinische Pädiatrie (05). https://doi.org/10.1055/s-0033-1343657
Mit CareLit weiterarbeiten